The goal of chemoprevention is to reduce the risk of cancer development by reversing or blocking the tumorigenic process through the use of pharmacologic or natural agents. To determine the potential role of genetic alterations in assessing cancer risk and in evaluating the efficacy of chemopreventive agents, we studied 22 patients with advanced premalignant lesions of the head and neck who were part of a prospective cancer prevention trial that is investigating a regimen of 13-cis-retinoic acid, interferon alfa, and ␣-tocopherol administered for 12 months or until disease progression. Methods: We used polymerase chain reaction analysis of microsatellite DNA sequences in cells from precancerous lesions to determine the frequencies of genetic alterations-namely, loss of heterozygosity (LOH) and microsatellite instability-at chromosomal loci that are commonly deleted in head and neck cancer. Results: Prior to treatment, 17 (81%) of 21, eight (44%) of 18, and eight (42%) of 19 patients who were informative (i.e., heterozygous) at chromosomes 9p21, 3p14, and 17p13, respectively, exhibited LOH in at least one of their lesion biopsy specimens. Among nine patients who exhibited LOH at chromosome 9p21 in pretreatment biopsy specimens and who had completed at least 5 months of therapy, the genetic loss persisted in eight-including three of the four patients who exhibited complete histologic responses (i.e., no evidence of dysplasia in their biopsy specimens). Implication: Our data suggest that clinical and histologic assessments of the response to chemopreventive agents may be insufficient to determine their efficacy and that critical genetic alterations could be used as independent biomarkers to augment the ability to evaluate the efficacy of such agents. [J Natl Cancer Inst 1998;90:1545-51]
It is now generally accepted that cancer is a genetic disease. Multiple genetic alterations in a single cell are required for a full malignant transformation in most human cancers (1) , including head and neck squamous cell carcinoma (HNSCC), one of the most common tumors worldwide (2) . Despite advances in the management of this disease during the past two decades, overall survival for patients with HNSCC has not improved significantly (3) .
Since exposure to exogenous carcinogens, such as tobacco products and alcohol, plays an important role in the development of HNSCC (4) , this disease may be preventable by eliminating carcinogen exposure. However, cells or clones that have already acquired genetic damage in critical genes may be prone to cancer development even without further exogenous carcinogen exposure. Also, unrecognized exogenous or endogenous carcinogens may continue to insult the tissues and cause progression to tumorigenesis. Chemoprevention-therapy designed to reduce or even reverse the carcinogenic process in vivo in individuals with a high risk of developing cancer-is a promising field of research. Investigators have rigorously tested the efficacy of numerous chemopreventive agents in a variety of clinical trials (5) (6) (7) . Because cancer incidence is currently the only reliable end point to determine chemopreventive efficacy, chemoprevention trials require large sample sizes and long-term follow-up and incur high costs. These factors limit our ability to evaluate a large number of promising chemopreventive agents. Therefore, it is urgent that researchers identify novel genetic or other markers that can accurately predict the risk of cancer development long before it occurs. When validated, these markers can then be used not only to select high-risk patients for chemopreventive therapy but also to serve as intermediate end-point markers for the evaluation of the efficacy of novel chemopreventive agents in much shorter, smaller, and less expensive trials.
In our previous study (8) , loss of heterozygosity (LOH) at chromosome locations 3p14 and 9p21 was found in 45% and 36%, respectively, of patients with oral leukoplakia, an oral premalignant lesion with a high risk of cancer development. This suggested that LOH at these chromosomal loci is a common genetic abnormality in early head and neck tumorigenesis. Of greater importance, the presence of LOH at these critical chromosomal loci was associated with a higher incidence of oral cancer (8) .
In the present study, we assessed whether LOH at critical chromosomal loci can be used as a genetic marker of potential chemopreventive efficacy, independent of clinical and histologic parameters currently in use for assessing the activity of chemopreventive agents. We examined LOH status at chromosomes 3p14, 9p21, and 17p13 before and after a chemopreventive intervention in patients with advanced oral or laryngeal premalignant lesions who were enrolled in our ongoing trial.
SUBJECTS AND METHODS
Patient population and samples. We studied a total of 22 patients with advanced premalignant lesions of the head and neck who are enrolled in our ongoing biochemoprevention trial at The University of Texas M. D. Anderson Cancer Center. The study was approved by an Institutional Review Committee, and all patients signed an informed consent form before they were enrolled. The lesions must have at least moderate dysplasia at the time of the enrollment. The patients were treated with 13-cis-retinoic acid (13-cRA) (100 mg/m 2 per day), interferon alfa (IFN ␣) (3 mU/m 2 twice weekly), and ␣-tocopherol (1200 IU/day) for 12 months. Four of the 22 patients were treated for less than 6 months of treatment because of intolerable drug toxicity, noncompliance, or ineligibility and thus are not eligible for response evaluation but are included in our baseline (before treatment) data analysis to maximize the sample size. Treatment effects were evaluated at 6 and 12 months by clinical examination and pathologic evaluations. Responses were classified as follows: complete response (CR), i.e., no gross lesion being observed in the region examined for clinical CR and no dysplastic change being observed in the biopsy specimens examined for histologic CR; partial response (PR), i.e., reduction in the sizes of the lesions by at least 50% for clinical PR and reduction in the severity of dysplasia (e.g., from severe dysplasia to moderate or mild dysplasia) for histologic PR; no change; or progressive disease (PD), i.e., increase in the sizes of the clinical lesions, increase in the severity of the dysplasia, or development of cancer. Fourteen patients were treated for at least 6 months and had tissue samples available for genetic analyses. All biopsy specimens of lesions were formalin fixed and paraffin embedded. A total of 79 biopsy samples from the 22 patients were obtained for the study, which consisted of 39 samples taken before treatment and 40 samples taken during or after treatment. Sections (4 m) from each sample were stained with hematoxylin-eosin, and one section from each specimen was reviewed by a pathologist (A. K. El-Naggar) for histologic features. Peripheral blood (2 mL) was obtained from each patient.
Microdissection and DNA extraction. The epithelial part of each lesion biopsy specimen was microdissected from serial sections of the biopsy sample by use of a 25 1 ⁄2-gauge steel needle under a stereomicroscope. After the microdissection, the samples were digested in 100 L 50 mM Tris-HCl (pH 8.0) containing 1% sodium dodecyl sulfate-proteinase K (0.5 mg/mL) (BoehringerMannheim, Indianapolis, IN) and incubated at 42°C for 24-36 hours. Digested products were purified by two treatments with phenol-chloroform. DNAs were then precipitated by use of the ethanol precipitation method in the presence of glycogen (Boehringer-Mannheim). For DNA extraction from blood samples, leukocytes were isolated by lysing red blood cells and subjected to digestion and DNA purification as mentioned above.
Microsatellite analysis. A few thousand nuclei were dissected from most of the samples for genetic analyses including determination of LOH and of p53 gene (also known as TP53) mutations. DNA from at least 150 nuclei was utilized for each polymerase chain reaction (PCR) amplification to avoid possible PCR artifacts caused by a small amount of DNA template. The markers used were D9S171 and D9S1747 at 9p21, D3S1285 and D3S1234 at 3p14, and TP53 at 17p13 (Research Genetics, Huntsville, AL). For PCR amplification, one of the primers for each marker was end-labeled with [␥-32 P]adenosine triphosphate (4500 Ci/mmol; ICN Biomedicals, Costa Mesa, CA) and T4 DNA polynucleotide kinase (New England Biolabs, Inc., Beverly, MA). PCR reactions were carried out in a 10-L volume containing 3% dimethyl sulfoxide, 1.5 mM deoxynucleoside triphosphate, 6.7 mM MgCl 2 , 0.4 M PCR primers including 0.01 M ␥-32 P-labeled primer, and 0.5 U of Taq DNA polymerase (Life Technologies, Inc. [GIBCO-BRL], Gaithersburg, MD). DNA was amplified for 40 cycles of 95°C for 30 seconds, 56-58°C for 60 seconds, and 70°C for 60 seconds in a temperature cycler (Hybaid; Omnigene, Woodbridge, NJ) in 500-L plastic tubes, followed by a 5-minute extension period at 70°C. The PCR products were separated on a 7% polyacrylamide-urea-formamide gel and then exposed to film for 12-48 hours at -80°C. LOH was defined as a more than 50% reduction in the intensity by visual inspection in one of the two alleles as compared with those in normal control panels. A patient was considered to exhibit LOH once one lesion biopsy specimen from the patient at baseline showed LOH for each chromosomal locus. However, to qualify as persistent LOH in samples taken during or after treatment, the observed LOH must have been in a lesion biopsy specimen taken from the same area where LOH was present at baseline. Microsatellite instability was defined as one or more new alleles appearing in lesion biopsy specimens but not in corresponding normal control DNAs.
Statistical analysis. The chi-squared ( 2 ) test was used to determine differences in genetic abnormalities among different patient populations and disease sites. All tests were two-sided, and P values were considered significant when they were equal to or less than .05. Only descriptive statistics were used to characterize the changes in LOH status before and after treatment in the current article because of the small sample size. A more comprehensive statistical analysis will be performed when the ongoing study is completed.
RESULTS

Clinical and Histologic Effects of Biochemoprevention
A total of 22 patients with advanced premalignant lesions of the head and neck in which moderate to severe dysplastic changes were identified were enrolled in an ongoing biochemoprevention trial supported by the National Cancer Institute. The patient population included 18 males and four females. Twenty of the subjects were either current or former smokers, and two were nonsmokers. Eight patients had oral lesions, while 14 patients had laryngeal lesions. All patients were given a regimen of 13-cRA, IFN ␣, and ␣-tocopherol for 12 months or until disease progression as described in the ''Subjects and Methods.'' Treatment was stopped early in three patients because of intolerable toxicity and noncompliance. Another patient was ineligible because an invasive tumor was present at the time that the treatment was started.
Among the 18 patients who completed at least 6 months of treatment and evaluation, seven had oral lesions and 11 had laryngeal lesions. Although two clinical CRs and one histologic PR were achieved in the seven patients with oral lesions, no histologic CR was observed in any of the patients. In fact, four of the patients had PD, including the development of invasive cancers in two patients and the development of new lesions in the other two during the treatment. The patient with histologic PR also developed an invasive cancer 6 months after completing the 12-month treatment. In contrast, six of 11 patients with laryngeal lesions achieved histologic CR and one achieved histologic PR (64% major histologic response rate). Clinical CR was also observed in four of the 11 patients, and clinical PR was seen in another four patients (73% major clinical response rate). It is noteworthy that one patient with both clinical CR and histologic CR of his laryngeal lesion developed invasive cancer in the site opposite to the original lesion 6 months after the completion of the 12-month therapy. The LOH status of the lesion biopsy specimens from this patient will be discussed in more detail later.
Frequent LOH at Critical Chromosomal Loci
To determine the frequencies of microsatellite alterations at chromosomal loci commonly deleted in HNSCC in patients with advanced premalignant oral or laryngeal lesions, a total of 39 premalignant lesion biopsy specimens taken before treatment from the 22 patients were analyzed by use of five highly polymorphic microsatellite markers located at 3p14 (D3S1285 and D3S1234), 9p21 (D9S171 and D9S1747), and 17p13 (TP53). LOH at 3p14 was found in eight (44%) of 18 informative (i.e., showing heterozygosity of microsatellite markers) patients and nine (29%) of 31 informative biopsy specimens, in at least one of the two markers. These results are comparable to those reported in our previous study (8) in which the lesions analyzed were less advanced (with only 38% of the lesions having dysplastic changes) than those analyzed in this study ( Table 1 ). The data indicate that the frequency of LOH at 3p14 does not increase with the severity of dysplasia and suggest that loss of the 3p14 region may play a role in tumor initiation in a subset of head and neck premalignant lesions. In contrast, LOH at 9p21 was found in 17 (81%) of 21 informative patients and 25 (69%) of 36 informative biopsy specimens, in at least one of the two markers. These frequencies are significantly higher (P<.01 for both patients and biopsy specimens; 2 test) than those found in our previous study (8) (Table 1) , which suggests that LOH at 9p21 is more frequent in advanced head and neck premalignant lesions and may play an important role in the early progression of the premalignant lesions in the head and neck. LOH at 17p13, a region that harbors the p53 tumor suppressor gene, was found in eight (42%) of 19 informative patients and 13 (39%) of 33 lesion biopsy specimens ( Table 1 ). The high frequency of LOH at this locus suggests a potential role of p53 in preinvasive head and neck tumorigenesis. Examples of LOH at these chromosomal loci in the lesion biopsy specimens are shown in Fig. 1 . It should be noted, however, that, although a striking difference in clinical and histologic responses following treatment was observed between patients with oral lesions and laryngeal lesions, no significant difference in LOH frequencies (all P>.05; 2 test) has been found at the three critical chromosomal loci tested (Table 2) .
Microsatellite instability was observed in only 16 (4.4%) of 361 successful microsatellite analyses (data not shown). The significance of the phenomenon in these lesions is unclear.
Persistent LOH at 9p21 Despite Clinical or Histologic Responses
To determine whether the LOH at these critical chromosomal loci that we observed in advanced head and neck premalignant lesions can be used as a measure of potential chemopreventive effects, we analyzed 38 biopsy specimens from 14 patients who had completed 6 or 12 months of treatment (except one patient who was treated for 5 months) or who had developed an invasive cancer and had tissue available. Of the 38 biopsy specimens, 31 were taken after 6 or 12 months of treatment; the remaining seven biopsy specimens were obtained 6 months after the completion of the 12-month treatment regimen or at the time of cancer development.
Among the 14 patients, 13 were informative in at least one marker at the 9p21 locus. Nine (69%) of the 13 informative patients exhibited LOH in this chromosomal region in at least one biopsy specimen taken before treatment. The status of microsatellite alterations in the 14 patients is presented in Fig. 2 . Although clinical responses were observed in five of the nine patients with LOH in 9p21 (CRs in patients 2, 6, 7, and 15; a PR ‡Reference (8) .
§All P values are two-sided. †All P values are two-sided.
in patient 1) and histologic responses in five (CRs in patients 1, 4, 6, and 15; a PR in patient 5) of the nine patients, LOH at 9p21 persisted in eight (89%) of the nine patients as seen in biopsy specimens taken after 6 or 12 months of treatment (Fig. 2) . Only one patient (No. 15) who had both clinical CR and histologic CR displayed no LOH in his 6-month biopsy specimen. It is interesting that one patient (No. 6) exhibited persistent LOH at 9p21 in biopsy specimens taken at 6 and 12 months, respectively, yet a lesion biopsy specimen taken 6 months after the completion of the 12-month treatment regimen showed no LOH at the same Fig. 2 . Microsatellite alterations and p53 gene mutations in lesion biopsy specimens taken before and after treatment. Met ‫ס‬ a metastatic lymph node; Ca ‫ס‬ progression to cancer; ᭹ ‫ס‬ loss of heterozygosity; r ‫ס‬ retention of two alleles; -‫ס‬ DNA could not be amplified; H ‫ס‬ homozygosity of two alleles; ‫ס‬ microsatellite instability; Y ‫ס‬ a p53 mutation was present; and N ‫ס‬ no p53 mutation was present. *The patient was treated for 5 months and included in the analysis despite lack of eligibility for clinical response evaluation.
marker (Fig. 3, A and B) . This patient has remained clinically and histologically free of disease since 6 months of treatment. It needs to be further determined whether the biochemopreventive therapy that we used has a time lag in the elimination of abnormal genetic clones. However, another patient (No. 11) whose initial lesion biopsy specimen lacked LOH at any of the markers tested before treatment had LOH in biopsy specimens taken 6 and 12 months after treatment, although a CR was documented both clinically and histologically (Fig. 3, C, D , and E). This patient developed an invasive cancer on his larynx on the side opposite to that of the original lesion 6 months after completing a 12-month treatment. Two other patients (Nos. 5 and 13) who developed invasive oral tumors also exhibited persistent LOH at 9p21 (Fig. 2) , which suggests that the appearance of LOH at critical chromosomal loci may predict the presence of a ''field defect'' and an increased risk of cancer development. Because the number of patients with LOH at 3p14 and 17p13 was small (three at 3p14 and three at 17p13) (Fig. 2) , it is not possible to determine the treatment effects at these chromosomal loci at this point in our trial.
DISCUSSION
LOH at different chromosomal regions has been identified frequently in human solid tumors and is considered to be a common mechanism to inactivate one of the two alleles of tumor suppressor genes in tumorigenesis (9) . (The second allele of a tumor suppressor gene is usually inactivated by point mutations or other mechanisms.) It is, therefore, widely used as a hallmark to indicate the presence of tumor suppressor genes at particular chromosomal regions (10) (11) (12) in studies aimed at the positional cloning of tumor suppressor genes.
In an earlier study (8) , we demonstrated that LOH at certain critical chromosomal regions, such as 3p14 and 9p21, is a common genetic event in early oral tumorigenesis. Patients with lesions bearing these genetic abnormalities had a higher risk of developing invasive cancers of the oral cavity (8) , which supports the hypothesis that tumor suppressor genes in these regions may be important in the malignant transformation and progression of oral squamous epithelium. Results from the current study confirm our previous findings. Moreover, we found that the Fig. 3. A) Histology of lesion biopsy specimens taken from patient 6 at baseline (severe dysplasia), 6 months (no dysplasia), and 12 months (no dysplasia) after treatment. B) Persistent loss of heterozygosity (LOH) for microsatellite marker D9S171 (chromosomal locus 9p21) in biopsy specimens taken from patient 6 at baseline, 6 months, and 12 months, but retention of two alleles in the biopsy specimen taken at 18 months. C and D) Histologic and clinical responses after 6 months of treatment in patient 11. The lesion biopsy specimen taken at baseline, but not the biopsy specimen taken at 6 months, displayed moderate dysplasia. A diffuse lesion was observed before treatment; this lesion caused edema and dysfunction of the right vocal cord. The lesion regressed after 6 months of treatment, and vocal cord function was restored. E) LOH was observed at three markers located at chromosomal loci 3p14, 9p21, and 17p13, respectively, in the biopsy specimen taken at 6 months of treatment from patient 11, but not in the biopsy specimen taken at baseline. Arrowheads indicate LOH (original magnification in panels A, C, and D ×400). N ‫ס‬ normal control.
frequency of LOH at the 9p21 region was significantly higher in patients with advanced head and neck premalignant lesions and was comparable to the frequency identified in patients with HNSCC (13, 14) . This is underscored by the fact that the p16 tumor suppressor gene (also known as CDKN2A) located at 9p21 is inactivated frequently in HNSCC (15, 16) . Inactivation of p16 has also been observed in lesion biopsy specimens from half of the patients with oral premalignant lesions and associated with LOH at 9p21 in the same panel of cases (17) , suggesting that LOH at the region is a major mechanism in the inactivation of p16 in head and neck premalignant lesions.
It is interesting that LOH at the TP53 locus (17p13) is noted frequently in high-grade dysplasia in this study (45% of the informative lesions and 50% of informative patients). Califano et al. (18) also found that 33% of dysplastic head and neck lesions and 47% of head and neck carcinomas in situ displayed LOH at 17p13. These data suggest that loss of 17p13 may be associated with early malignant progression of head and neck lesions. Because the locus analyzed is located within the p53 tumor suppressor gene, it is not surprising that p53 gene mutations were detected in lesion biopsy specimens from five (24%) of 21 patients (Shin DM, Mao L: unpublished observation). However, many lesions with LOH at the TP53 locus do not exhibit p53 mutations in the remaining alleles and, conversely, lesions with p53 gene mutations were not always accompanied by LOH at the TP53 locus (Fig. 2) , suggesting the possible presence of another tumor suppressor gene located near p53. Alternatively, inactivating one copy of p53 may play a role through a gene-dose effect in accelerating an accumulation of genetic damage at that stage of tumorigenesis.
The most striking finding in this study is the discordance between genetic status and the clinical and histologic responses, indicating a lag between the phenotypic and the underlying genetic responses to treatment. Although more genetic abnormalities are generally found in later stages of tumorigenesis (such as in invasive cancer), some of the genetic abnormalities can be identified frequently in very early stages of tumorigenesis (8, 18) , even in normal-appearing epithelia of the lung (19) and breast (20) . This observation suggests that genetic abnormalities may exist independent of morphologic parameters and can serve as markers to extend our ability to diagnose and monitor the disease.
In this study, all patients whom we studied had high-grade dysplastic head and neck lesions before treatment. Agents such as 13-cRA and IFN ␣ used in this study can experimentally induce epithelial differentiation (21, 22) . The short-term use (3 months) of high-dose 13-cRA was proven effective in reversing oral leukoplakia lesions (6) . However, the relapse rate was high (more than 50% of patients with responses) upon discontinuation of treatment (6) . In a later clinical chemoprevention trial, the response rate in patients with oral leukoplakia treated with lowdose 13-cRA for 12 months was 55% versus 8% in patients with oral leukoplakia treated with ␤-carotene for 12 months (7). It is noteworthy that the overall cancer incidence in patients treated with 13-cRA was identical to that in patients treated with ␤-carotene in the long-term follow-up (23) . However, a delay in developing invasive tumors in the oral cavity was noted in patients treated with 13-cRA (median time, 37 months versus 29 months in patients treated with ␤-carotene) (23) . Together with our finding that LOH at 9p21 is persistent in the biopsy specimens following treatment-regardless of complete clinical and histologic responses-in a substantial number of patients in this study, we contend that treatment may induce histologic differentiation in dysplastic epithelium to cause the observed clinical responses. It is possible, however, that some of the advanced premalignant clones with additional genetic abnormalities, such as mutations of p53, may be sensitive to the agents and their growth may be repressed by the treatment (Shin DM, Mao L: unpublished observation). Clones with early genetic abnormalities, such as LOH at 9p21, or subclones with other genetic abnormalities that are insensitive to the agents remain and become the sources of disease progression or recurrence if no further effective treatment is administered. Therefore, prolonged maintenance treatment or administration of other effective agents may eventually repress growth of the clones with early genetic abnormalities or clones resistant to current agents. Studies (24, 25) have indicated that 4-hydroxyphenyl retinomide (4-HPR) can induce apoptosis and has activity in neoplastic cells that are resistant to other retinoic acids. 4-HPR has a favorable toxicity profile (26) and has been used in several chemoprevention trials. Whether this promising chemopreventive agent can eliminate preneoplastic clones will be determined in our next clinical trial.
The different responses to the biochemopreventive agents by oral lesions and laryngeal lesions that were observed in this study may be explained by the presence of distinct genetic alterations in lesions located at different sites. The development of laryngeal dysplastic lesions may require fewer genetic alterations or distinct tumorigenic pathways compared with oral dysplastic lesions. However, no difference in LOH frequencies was observed between oral lesions and laryngeal lesions. It is possible that the three chromosomal loci tested in this study are commonly involved in tumorigenesis of both anatomic regions, whereas other genetic abnormalities, specific for a particular region, are still unidentified. Further extensive analysesincluding more chromosomal loci, specific oncogenes, and tumor suppressor genes-should provide additional information for the hypothesis. Alternatively, different gene expression profiles between oral and laryngeal epithelia may result in a distinct response to the biochemopreventive agents. Nevertheless, LOH at 9p21 is the most common genetic event identified so far in early tumorigenesis within the head and neck, and this event may serve as a marker of an increased risk of cancer development and of treatment effects in patients with premalignant head and neck lesions.
In summary, these data provide the first direct molecular support 1) for the clinical hypothesis that the high recurrence of premalignant lesions (in responding patients) shortly after stopping chemopreventive therapy and the resumption of progression to cancer development (after a delay in treated patients) are the result of persisting clonal genetic abnormalities that are unaffected by the treatment and 2) for the utility of genetic markers as intermediate end-point biomarkers of chemoprevention and as independent predictors of cancer recurrence and/or risk. Therefore, phenotypic modulations after chemopreventive intervention, such as reversed differentiation patterns and reduced size of lesions, may not be sufficient to indicate efficacy of the treatment. The phenotypic parameters should be combined with mea-surement of critical genetic markers in assessment of the efficacy of novel chemopreventive agents. We have currently incorporated these genetic markers into our clinical chemoprevention trials as a potential intermediate end point. However, because the sample in this study is small, we are unable to provide a meaningful statistical basis to make general recommendations. Further studies with a larger sample and longer follow-up are required to extend our understanding of the discordance observed, not only between clinical/histologic response and continuing persisting genetic abnormalities but also between lack of clinical response and resolution of genetic abnormalities.
